secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nano Dimension Ltd. (NNDM)
CIK:        0001643303
Form:       8-K
Filed at:   2026-08-18T12:00:15+00:00
Accession:  0001193125-26-354738
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Nano Dimension adds Nadav Kidron to board; Infinite Epigenetics exclusivity lapses without deal
--------------------------------------------------------------------------------

- Nadav Kidron appointed to Nano Dimension board as Class II independent director, effective Aug 16, 2026; joins Audit and Compensation committees.
- Kidron is CEO of Oramed Pharmaceuticals (ORMP) since 2006; also director at Lifeward (LFWD) and Alpha Tau (DRTS).
- 30-day exclusivity period under non-binding term sheet with Infinite Epigenetics expired July 15, 2026; no definitive agreement reached.
- As of Aug 16, 2026, parties have not reached agreement on definitive terms; no further details disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1643303/000119312526354738/0001193125-26-354738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1643303/000119312526354738/nndm-20260816.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-354738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer